UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Bisphosphonate Related Osteonecrosis of the Jaw: A Study of 18 Cases Associated with Fungal Infection

International Journal of Dentistry, 2014-01, Vol.2014 (2014), p.869067-5

2014

Volltextzugriff (PDF)

Étude de l’infiltrat inflammatoire dans les neurofibromes dysplasiques au cours de la neurofibromatose 1 : quelle pourrait être la place de l’immunothérapie dans le traitement des tumeurs des malades NF1 ?

Annales de dermatologie et de vénéréologie, 2018-12, Vol.145 (12), p.S128-S129

2018

Volltextzugriff (PDF)

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

The New England journal of medicine, 2021-04, Vol.384 (16), p.1529-1541

2021

Volltextzugriff (PDF)

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Annals of oncology, 2021-09, Vol.32 (9), p.1148-1156

2021

Volltextzugriff (PDF)

Mutations in the pre-replication complex cause Meier-Gorlin syndrome

Nature genetics, 2011-04, Vol.43 (4), p.356-359

2011

Volltextzugriff (PDF)

Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen

Human molecular genetics, 2013-01, Vol.22 (1), p.1-17

2013

Volltextzugriff (PDF)

201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study

Annals of oncology, 2023-10, Vol.34, p.S262-S262

2023

Volltextzugriff (PDF)

179TiP EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy

Annals of oncology, 2020-05, Vol.31, p.S80-S80

2020

Volltextzugriff (PDF)

Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss

Nature genetics, 2011-04, Vol.43 (4), p.303-305

2011

Volltextzugriff (PDF)

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer

ESMO open, 2022-12, Vol.7 (6), p.100651, Article 100651

2022

Volltextzugriff (PDF)

The genetic basis of DOORS syndrome: an exome-sequencing study

Lancet neurology, 2014, Vol.13 (1), p.44-58

2014

Volltextzugriff (PDF)

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

Annals of oncology, 2018-10, Vol.29, p.viii654-viii654

2018

Volltextzugriff (PDF)

Phase I/IIA Study with CNS-Targeted Liposomal Doxorubicin (2B3-101) in Patients with Brain Metastases (BM) From Breast Cancer (BC) and Other Brain Tumors

Annals of oncology, 2014-05, Vol.25, p.i25-i25

2014

Volltextzugriff (PDF)

347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

Annals of oncology, 2020-09, Vol.31, p.S386-S386

2020

Volltextzugriff (PDF)

348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)

Annals of oncology, 2020-09, Vol.31, p.S386-S387

2020

Volltextzugriff (PDF)

Mutations in the gene encoding filamin B disrupt vertebral segmentation, joint formation and skeletogenesis

Nature genetics, 2004-04, Vol.36 (4), p.405-410

2004

Volltextzugriff (PDF)

Lurbinectedin (PM01183) administered once (D1) every 3 weeks (q3w) in combination with capecitabine (XEL) in patients (pts) with metastatic breast (MBC), colorectal (CRC) or pancreatic (PaC) cancer

Annals of oncology, 2016-10, Vol.27, p.vi125-vi125

2016

Volltextzugriff (PDF)

1845PSafety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

P08.03 2B3-101, GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS AND BREAST CANCER BRAIN METASTASES

Neuro-oncology (Charlottesville, Va.), 2014-09, Vol.16 (suppl 2), p.ii50-ii51

2014

Volltextzugriff (PDF)

Abstract P2-05-17: ARGX-111 depletes MET-expressing circulating tumor cells via enhanced ADCC, resulting in inhibition of metastasis

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P2-P2-05-17

2016

Volltextzugriff (PDF)

DOORS syndrome: Phenotype, genotype and comparison with Coffin-Siris syndrome

American journal of medical genetics. Part C, Seminars in medical genetics, 2014-09, Vol.166C (3), p.327-332

2014

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(36)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bisphosphonate Related Osteonecrosis of the Jaw: A Study of 18 Cases Associated with Fungal Infection

Étude de l’infiltrat inflammatoire dans les neurofibromes dysplasiques au cours de la neurofibromatose 1 : quelle pourrait être la place de l’immunothérapie dans le traitement des tumeurs des malades NF1 ?

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Mutations in the pre-replication complex cause Meier-Gorlin syndrome

Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen

201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study

179TiP EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy

Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer

220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD

The genetic basis of DOORS syndrome: an exome-sequencing study

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)

Phase I/IIA Study with CNS-Targeted Liposomal Doxorubicin (2B3-101) in Patients with Brain Metastases (BM) From Breast Cancer (BC) and Other Brain Tumors

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial

347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)

Mutations in the gene encoding filamin B disrupt vertebral segmentation, joint formation and skeletogenesis

Lurbinectedin (PM01183) administered once (D1) every 3 weeks (q3w) in combination with capecitabine (XEL) in patients (pts) with metastatic breast (MBC), colorectal (CRC) or pancreatic (PaC) cancer

1845PSafety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

Meier-Gorlin syndrome genotype-phenotype studies: 35 individuals with pre-replication complex gene mutations and 10 without molecular diagnosis

P08.03 2B3-101, GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS AND BREAST CANCER BRAIN METASTASES

Abstract P2-05-17: ARGX-111 depletes MET-expressing circulating tumor cells via enhanced ADCC, resulting in inhibition of metastasis

DOORS syndrome: Phenotype, genotype and comparison with Coffin-Siris syndrome

Suchergebnisse filtern